Project Grant R01HL180491
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $1.211 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate neutral sphingomyelinase (NSMASE) in cardiac mechanosensing and mechanical regulation of the heart. The project addresses NSMASE as a critical membrane enzyme involved in sphingolipid metabolism that regulates both normal physiological heart function in response to acute changes in cardiac...
- The National Heart, Lung, and Blood Institute (NHLBI), part of the Department of Health and Human Services National Institutes of Health, awarded The Medical College of Wisconsin, Inc. $792,011 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to validate plasma cell-free DNA (CFDNA)—including nuclear and mitochondrial variants—as a clinically actionable biomarker for predicting critical post-surgical events in infants undergoing complex congenital heart surgery....
- The National Heart, Lung, and Blood Institute awarded $108,656 to the University of Wisconsin–Madison on March 3, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize the molecular mechanisms of phospholamban R14DEL cardiomyopathy. The recipient will use high-resolution mass spectrometry–based proteomics, human clinical samples, and patient-specific human induced pluripotent stem cell–derived cardiomyocytes to investigate how cardiac proteoform alterations drive...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $174,621 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiac magnetic resonance imaging (CMR) techniques for monitoring congenital heart disease using ultra-low field (ULF) MRI systems. The recipient will adapt CMR to an inexpensive, unshielded, open-geometry ULF MRI system and apply machine learning techniques to mitigate hardware limitations and...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $747,262 on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define the multi-omics landscape of phospholamban-induced cardiomyopathy for precision medicine. The research applies top-down proteomics to study post-translational modifications, genetic variants, and splicing isoforms in phospholamban (PLN) gene variants, specifically the PLN-R14DEL deletion associated with...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin–Madison $151,040 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the assembly and localization of HERG channel cotranslational complexes in cardiac tissue. The research examines how heart cells co-regulate functionally related ion channels at the translational level during protein biosynthesis, with focus on HERG1A and HERG1B channel assembly. The project uses...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $152,168 on February 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the developmental programming of hematopoietic stem and progenitor cells using an integrin A4 mutant zebrafish model. The research characterizes how hematopoietic stem and progenitor cells interact with their microenvironment during mammalian development. The award funds analysis of transcriptomic...
- The National Heart, Lung, and Blood Institute awarded the Regents of the University of Minnesota $763,046 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a rapid cardiac magnetic resonance imaging (CMR) protocol for heart failure diagnosis. The project addresses barriers to clinical adoption of CMR in heart failure care by reducing examination time from 45–60 minutes to approximately 10 minutes and eliminating the need for...
- The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison $581,307 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mutation-specific responses to myosin inhibitors in human iPSC models of hypertrophic cardiomyopathy. The research evaluates how different HCM-causing mutations in genes encoding cardiac sarcomeric proteins respond to mavacamten, a myosin ATPase inhibitor approved to treat obstructive HCM....
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $760,465 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop deep learning methods that advance cardiac magnetic resonance strain imaging for personalized cardiac resynchronization therapy treatment planning. The award funds development of deep strain networks to rapidly and accurately predict myocardial displacements from cardiac magnetic resonance imaging, addressing...
The National Heart, Lung, and Blood Institute awarded the University of Wisconsin - Madison a Project Grant of $661,286 on July 22, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a combined fetal magnetocardiography and echocardiography platform using optically-pumped magnetometer quantum sensors to enable simultaneous assessment of fetal cardiac electrical rhythm and structural function. Current prenatal diagnostic methods rely heavily on fetal echocardiography, which excels in structural and functional assessment but cannot reliably evaluate electrophysiological abnormalities; fetal magnetocardiography conversely provides superior electrical rhythm assessment but lacks structural information. The project will develop signal processing methods to integrate magnetocardiography data with echocardiographic images through an integrated probe that automatically registers optically-pumped magnetometer sensor positions and orientations relative to ultrasound images of the fetus. Beamforming, adaptive filtering, maximum likelihood estimation, and machine learning methods will improve signal-to-noise ratio and reduce signal dropout from fetal movement. The award will also develop methodology to perform signal-averaging of echocardiographic data using magnetocardiography QRS complexes as precise time markers, enabling temporal alignment of echocardiographic tracings from different cardiac regions and mitigation of variability in mechanical interval measurements. Performance of work occurs in Madison, Wisconsin 53715. The period of performance extends through March 31, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $661.3k | 7/24/26 |